Polyplus-transfection SA, has announced that ExcellGene SA has signed an extended supply agreement for Polyplus-transfection polyethylenimine (PEI) based transfection reagents.
Polyplus-transfection will supply ExcellGene with batches of high quality linear PEI transfection reagent which is specifically formulated and subject to appropriate quality controls (transfection activity and microbiological tests) that ensure reliable, safe and reproducible protein production in medium to large scale.
In addition, by purchasing PEI from Polyplus-transfection, ExcellGene benefits from an implied license regarding Polyplus’ intellectual property rights for the use of PEI in transient and stable transfection.
“We are truly delighted to sign a supply agreement for PEI for transfection with ExcellGene, a recognized leader in providing process solutions for the pharmaceutical and biotech industry in the field of recombinant expression technologies,” said Mark Bloomfield, CEO of Polyplus-transfection. “This agreement demonstrates the superiority of Polyplus PEI for bioproduction and the value of our intellectual property rights and knowhow in the field of PEI-mediated nucleic acid delivery.”
“Known for our highly innovative approaches in protein production from mammalian cells we have studied extensively a large variety of DNA transfer systems and have found Polyplus polyethylenimine of highest quality and serving best our needs,” said Dr Maria De Jesus, chief operating officer of ExcellGene.
Prof Florian Wurm, founder and interim CEO of ExcellGene added: “In our highly regulated industry, the reliable sourcing of materials for any type of manufacturing is key to the confidence we wish to establish with our clients, since the final goal of our work is the provisioning of highest value protein therapeutics to the treating doctor and the patient in need.”
Financial terms were not disclosed.